News Agency

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

  • Written by PR Newswire

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preserving weight loss in Obesity

LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech company focused on novel drug development for...

Read more: Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal...

Last-Mile Delivery Tracking: Ensuring Efficiency and Customer Satisfaction

As our lives increasingly revolve around the internet, especially with the current boom in eCommerce, it’s no surprise that customer expectations have become more demanding. Consumers now expect their goods to be delivered as quickly as possible, with a smooth... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion